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Abstract 
Background & Objective: The autosomal dominant spinocerebellar ataxias (SCAs) belong to 
a large and expanding group of neurodegenerative disorders. SCAs comprise more than 40 
subtypes characterized by progressive ataxia as a common feature. The most prevalent diseases 
among SCAs are caused by CAG repeat expansions in the coding-region of the causative gene 
resulting in polyglutamine (polyQ) tract formation in the encoded protein. Unfortunately, there 
is no approved therapy to treat cerebellar motor dysfunction in SCA patients. In recent years, 
several studies have been conducted to recognize the clinical and pathophysiological aspects of 
the polyQ SCAs more accurately. This scientific progress has provided new opportunities to 
develop promising gene therapies, including RNA interference and antisense oligonucleotides. 
Conclusion: The aim of the current work is to give a brief summary of the clinical features of 
SCAs and to review the cardinal points of pathomechanisms of the most common polyQ SCAs. 
In addition, we review the last few years promising gene suppression therapies of the most 
frequent polyQ SCAs in animal models, on the basis of which human trials may be initiated in 
the near future. 
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 1. Introduction 
The spinocerebellar ataxias (SCAs) are progressive neurodegenerative diseases with autosomal 
dominant inheritance. The global prevalence of SCAs is estimated to be approximately 1-
5:100,000 people, with SCA3 as the most prevalent subtype [1, 2]. Cerebellar ataxia is the major 
clinical feature of this group, accompanied by the involvement of other neurological systems 
connected to the cerebellum with varying severity of symptoms. Knowledge of the genetic 
background of the SCAs is continuously expanding due to the development of DNA 
sequencing, resulting in more than 40 subtypes of SCA [3]. The most common genetic variation 
is the CAG repeat expansion in the coding region of the gene, which encodes polyglutamine 
(polyQ) in the corresponding protein. PolyQ SCAs include SCA1, 2, 3, 6, 7, 17 and 
dentatorubro-pallidoluysian atrophy (DRPLA) (Table 1) [4]. Besides the polyQ group, disease-
causing repeat expansions have been identified in non-coding regions of the gene in some SCAs 
(SCA8, 10, 12, 31, 36, 37) similarly to Friedreich ataxia, which is the most common autosomal 
recessive cerebellar ataxia (Table 2) [4, 5]. Moreover, conventional mutations (point mutations, 
deletions, insertions) can cause certain types of SCA, including SCA5, 11, 13, 14, 15/16, 19/22, 
21, 23, 26-29, 34, 35, 38, 40-47 (Table 3) [4-9], whereas in some forms of SCA, including 
SCA4, 18, 20, 25, 30 and 32 only the genetic loci, but not the responsible gene, have been 
identified. 
The low prevalence, genetic diversity and different pathomechanisms of SCAs are the major 
difficulties in drug development. Probably the most comprehensive clinical description of 
patients with SCAs (more than 12 000 individuals) was performed by Rossi et al. in 2014 [10]. 
Accordingly, the aim of the current work is to give a brief summary of the clinical picture of 
SCAs including descriptions of the novel ones, and to overview the main pathological 
alterations and therapeutic options of the most common polyQ SCAs (SCA1, 2, 3, 6, 7) 
similarly to Picher-Martel et al. and Hadjivassiliou, who reported these aspects of the autosomal 
recessive and immune-mediated ataxias, respectively [11, 12]. 
 
2. Overview of characteristic alterations with a focus on potential drug targets 
Truncal and limb ataxia are the most prevalent symptoms in SCAs, therefore they are not 
appropriate features to distinguish between the different subtypes. In turn, other neurological 
signs, ophthalmological and hearing abnormalities are present with various frequencies in the 
distinct forms of SCAs, therefore the assessment of these signs may have a special importance 
during clinical examination. 
Autosomal dominant cerebellar ataxias form a large and heterogeneous group of 
neurodegenerative disorders. The different genetic backgrounds have resulted in diverse 
pathomechanisms, while the low prevalence and the diagnostic difficulties of SCAs are 
obstacles in recruiting sufficient numbers of patients for a well-designed therapeutic study. Due 
to these difficulties, there is no approved therapy to treat cerebellar motor dysfunction in SCA 
patients [3]. 
2.1. PolyQ SCAs 
The polyQ SCAs are the most frequent and the earliest-discovered SCAs, typically 
characterized by a progressive disease course. A correlation exists between the number of CAG 
repeats and severity of the disorder: the larger the CAG repeat number, the more severe the 
clinical phenotype and the earlier the age of onset. Anticipation has been observed in this group 
of neurodegenerative disorders due to the instability of the expanded repeat sequence during 
meiosis. The pathomechanism of these subtypes is the most extensively explored because of 
the identical genetic alteration (CAG repeat expansion in the coding region) and their frequent 
occurrence among SCAs. In polyQ SCAs, similarly to other polyglutamine disorders, the 
expansion of glutamine causes altered protein conformation and aggregation, resulting in a 
reduction in the physiological function of the protein and consequential toxic effects, which 
eventually lead to increased neuronal vulnerability and cell death. Gene suppression studies 
may yield options for the treatment of polyglutamine-repeat disorders. Most of these studies 
were performed in Huntington’s disease mouse models and utilized RNA interference (RNAi) 
and antisense oligonucleotides (ASO) [13].  
SCA1 
SCA1 is the first described subtype, characterized by a mean age of onset in the fourth decade, 
however it can range from childhood to late adulthood. In addition to truncal and gait ataxia, 
dysarthria and other cerebellar signs, ophthalmoparesis, pyramidal signs, dysphagia and bulbar 
signs are the most prevalent neurological abnormalities. Mild cognitive impairment, lower 
motoneuron involvement, deep sensory deficits and autonomic failure can be observed in some 
patients. SCA1 has the fastest progression of all SCAs with an annual increase of 2.11 points 
on the Scale for the Assessment and Rating of Ataxia (SARA) [14]. The characteristic brain 
MRI shows severe cerebellar and brainstem atrophy, whereas the neuropathological findings 
include severe degeneration in the primary motor cortex, basal forebrain, thalamus, red nucleus, 
motor cranial nerve nuclei (nerves III, IV, and VII-XII), vestibular nuclei, inferior olive, 
Purkinje cell layer and all deep cerebellar nuclei [15]. 
The disease-causing gene is ATXN1, located on chromosome 6, and encodes the protein ataxin-
1. In the healthy population the CAG repeat number is less than 35, with repeats longer than 20 
CAG triplets containing 1-3 CAT repeat interruptions, which code histidine. If the CAG repeat 
number is between 36 and 44, the pathogenicity depends on the presence of CAT interruptions. 
The presence of CAT impaction results in the absence of disease, while the absence of CAT 
interruption forms a mutable normal (36-38 CAG repeats) or full-penetrance allele (39-44 CAG 
repeats) [16, 17]. 
In the case of 30 CAG repeats, ataxin-1 is an 816 amino acid-containing protein with several 
domains and functionally important motifs (Fig. 1). Ataxin-1 protein interacts with several 
nuclear components, including RNAs, transcriptional regulators and many other proteins 
detailed below. A nuclear localization signal (NLS) motif is located near the C-terminus of the 
protein, which directs the protein to the nucleus [18]. If the CAG repeat number is in the normal 
range, ataxin-1 can enter the nucleus and it is able to exit it as well. On the other hand, in the 
case of pathological CAG repeat numbers, ataxin-1 cannot escape from the nucleus, which is 
the primary site of pathogenesis. Klement et al. described that a point mutation in the NLS 
motif (K772T) prevents ataxin-1 (82Q) from entering the Purkinje cell nucleus and this 
transgenic mouse model does not develop ataxia or Purkinje cell pathology. This observation 
suggests that mutant ataxin-1 must be transported to the nucleus to cause disease. Nevertheless, 
the self-association domain of the protein (between amino acids 495 and 605), which plays a 
role in the formation of nuclear aggregates, does not have such a crucial function in the disease 
pathogenesis [18, 19].  
Another important region of ataxin-1 is the AXH domain, a 130 amino acid long part of the 
protein interacting with a transcriptional corepressor SMRT (silencing mediator of retinoic acid 
and thyroid hormone receptors) and capicua (CIC), which is a transcriptional repressor protein 
[20, 21]. This interaction with CIC is very important because ataxin-1 can not bind DNA alone, 
while CIC has DNA-binding capability, thus ataxin-1 indirectly attaches to DNA and takes part 
in transcription [22]. Besides the AXH domain, the U2AF homology motif (UHM) is located 
near the C-terminus of ataxin-1. UHM is also an interaction point of the protein, where it 
connects to the RNA splicing factor RBM17 [23]. Lim and colleagues described that polyQ 
ataxin-1 prefers the formation of ataxin-1-RBM17 complex compared to ataxin-1-CIC 
complex, resulting in an imbalance between transcription and RNA splicing, which causes the 
pathogenesis of the disease. In addition to the polyglutamine tract, a phosphorylation of Ser776 
(a phosphorylation site) can also contribute to the formation of the ataxin-1-RBM17 complex 
(Fig. 1) [24]. A recent study published by Bondar et al. delineated that Drosophila p21-activated 
kinase 3 (PAK3) is a modulator of ataxin-1. Loss-of-function of Drosophila PAK3 or PAK1 
protein can reduce ataxin-1 levels, improving the SCA1 phenotype, therefore pharmacological 
inhibitors of PAK might be potential therapeutics for SCA1 [25]. 
Three previous RNAi studies were performed using recombinant adeno-associated viruses 
(AAV) expressing short hairpin RNA (shRNA) or micro RNAs (miRNAs) targeting the ATXN1 
gene in transgenic or knock-in mouse models [26-28]. These researches showed significant 
knockdown of ataxin-1 levels and improvement in behavioural, molecular and 
neuropathological phenotypes. Another miRNA study executed in rhesus macaques also 
provided promising results [29]. 
The expanding knowledge of the pathomechanism of SCA1 may provide therapeutic 
opportunities in the future, including the reduction of PAK3 activity, increasing CIC levels, 
dephosphorylation of pSer776 and modification of NLS (K772T). In addition, advances in 
RNAi studies in animal models may initiate human therapeutic trials in the near future, similar 
to those for Huntington’s disease. 
SCA2 
SCA2 is globally the second most frequent SCA, with a large founder population in Cuba [30]. 
The age of onset varies from early childhood to late adulthood with a mean onset in the early-
30s. Anticipation may be considerably pronounced in SCA2, so much so that extreme CAG 
repeat length (>200) may occur, resulting in disease onset at infancy [31]. The most prevalent 
extracerebellar features are slow saccades, ophthalmoparesis, dysphagia, bulbar signs, 
parkinsonism, deep sensory alterations and urinary dysfunction. Similar to SCA1, the main 
characteristic pathological finding is olivopontocerebellar atrophy, but dopaminergic neurons 
in the substantia nigra, nigrostriatal pathways and neurons in the pallidum are more severely 
affected, whereas the deep cerebellar nuclei are relatively spared [15]. 
In SCA2 the affected gene is ATXN2, located on chromosome 12, determining the protein 
ataxin-2. In healthy individuals CAG repeat number is 31 or fewer, while alleles with 33 or 
more repeats are pathogenic. Alleles with 32 CAG repeats are called intermediate with 
unknown significance, because they do not result in obligatory disease development. 
The ATXN2 gene with 23 CAG repeats encodes a 1313 amino acid-containing protein called 
ataxin-2. Previous studies revealed that polyQ ataxin-2 microaggregates were found only in the 
cytoplasm, but not in the nucleus, of Purkinje cells, which are the primary targets in SCA2 [32]. 
Moreover, ataxin-2 does not contain a nuclear localization signal in contrast to ataxin-1 [32]. 
These observations support the hypothesis, that ataxin-2 functions in the cytoplasm. Ataxin-2 
plays a role in RNA metabolism, as shown by studies indicating that ataxin-2 has specific motifs 
which enable interactions with proteins involved in RNA metabolism. These patterns are like-
Sm motif (LSm), polyadenylate-binding protein (PABP)-interacting motif of ataxin-2 (PAM2) 
and the C-terminus of ataxin-2 which can connect to the ataxin-2 binding protein 1 (A2BP1) 
(Fig. 2) [33-35]. Satterfield et al. reported that ataxin-2 and its Drosophila homolog, ATX2 
interconnect with polyribosomes and PABP, an important regulator of mRNA translation. Two 
regions of ATX2 are independently involved in the assembly of ATX2 with polyribosome, the 
LSm/LSm-associated domain (LSmAD) and the PAM2 motif. Besides this, PAM2 is also 
involved in the connection between ATX2 and PABP, therefore ATX2 can bind mRNA directly 
(through its LSm/LSmAD domain) and indirectly (through PABP), as well. These interactions 
suggest that ataxin-2 has a major role in translational regulation [36].  
Other studies also confirmed that ataxin-2 regulates RNA processing and protein translation. 
These researches are based on observations that ataxin-2 interacts with the DEAD/H-box RNA 
helicase DDX6, which is a component of stress granules (SGs) and processing bodies (P-
bodies). Another component of SGs is PABP, a previously described interaction partner of 
ataxin-2. SGs and P-bodies are the main compartments for the regulation of mRNA stability, 
translation and degradation, while the assembly of these intracellular units depends on cellular 
ataxin-2 concentration [37]. Moreover, the ataxin-2 paralog, called ataxin-2-like, has similar 
interaction partners (RNA helicase DDX6, PABP), whereas it is a component of SGs and its 
intracellular level regulates the induction of SGs and P-bodies [38].  
The ATXN2 gene with intermediate-length CAG repeats (27-33) is associated with amyotrophic 
lateral sclerosis (ALS) as a susceptibility gene. This susceptibility was strengthened by animal 
and cellular studies demonstrating that ataxin-2 is a remarkable modifier of TAR DNA-binding 
protein 43 (TDP43), which is involved in RNA metabolism and has a major role in the 
pathogenesis of ALS [39].  
We currently have a lot of information about the interactions and function of normal glutamine-
containing ataxin-2, however it is still unknown how the polyglutamine tract causes the disease. 
Two major hypotheses exist. The first is that the polyQ tract alters the interactions of ataxin-2 
and its role in RNA metabolism, i.e. causing a loss of its physiological function. The second 
suggests that polyQ ataxin-2 leads to perturbations in RNA metabolism, causing a toxic gain-
of-function (Fig. 2). 
Scoles et al. published an article about screening antisense oligonucleotides directed at the 
ATXN2 gene in mouse models in 2017. ASO7, one of these examined ASOs, showed 
encouraging results, including reduced cerebellar ATXN2 mRNA and protein levels and 
improved motor function in mice [40]. 
On the basis of the scientific results, the number of potential therapeutic targets is very limited, 
in contrast to SCA1. However, promising animal studies have been presented about the testing 
of ASO. Nevertheless, further pathophysiological studies are needed. 
SCA3 
SCA3, also known as Machado-Joseph disease (MJD) or Azorean ataxia, is the most common 
autosomal dominantly inherited ataxia worldwide. The prevalence of SCA3 is at least 50% of 
all SCAs in some countries, including Germany, Japan, Portugal, Brazil and Taiwan [41-47]. 
The clinical phenotype shows great diversity and therefore currently 5 different clinical 
subtypes can be distinguished. Type 1 is an early onset (<20 years) progressive disorder with 
pyramidal signs, ataxia and extrapyramidal features including bradykinesia, rigidity and 
dystonia. Type 2 is the most frequent form, characterized by later age of onset (20-50 years), 
cerebellar ataxia, pyramidal symptoms and progressive external ophthalmoplegia. Type 3 has 
a later onset than the previous types, generally between 40 to 75 years and the typical symptoms, 
besides ataxia, are lower motoneuron signs with muscle atrophy and motor neuropathy. These 
are the classical phenotypes of MJD, while type 4 and 5 are the most infrequent forms 
characterized by parkinsonism, ataxia and pure spastic paraplegia [48]. Pathologically, the 
primary motor cortex, the basal forebrain, the thalamus and the deep cerebellar nuclei are not 
so severely affected as compared to SCA1, while the brainstem nuclei and the basal ganglia are 
considerably damaged, as in SCA2 [15]. 
Machado-Joseph disease is caused by abnormally expanded CAG repeats in the ATXN3 gene, 
located on chromosome 14, and encoding the protein ataxin-3. Normal alleles contain 12 to 44 
CAG repeats and more than 90% of them have fewer than 31 CAG repeats. In classic SCA3 
patients, the CAG repeat number ranges from ~60 to 87, while there is an intermediate range 
between the normal and full penetrance alleles, presenting with a non-classical form of MJD 
[48]. 
Ataxin-3 is an evolutionarily conserved 42 kDa protein which is a deubiquitinating enzyme 
(DUB), regulating ubiquitin (Ub)-dependent protein modulation (Fig. 3) [49]. The catalytic 
Josephin domain (JD) is located at the N-terminus of the ataxin-3 protein, containing two 
ubiquitin-binding sites and two nuclear export signals (NES). At the C-terminus of ataxin-3 
there are two or three ubiquitin-interacting motifs (UIMs), the polyQ tract and the nuclear-
localization signal (NLS) [48]. Presumably, JD and UIMs cooperate in positioning and binding 
the polyUb chains and JD performs the cleavage. Ataxin-3 preferentially binds polyUb 
substrates, however it can deubiquitinate monoUb chains as well. Intracellular localization of 
ataxin-3 has complex regulation and its primary intracellular position is uncertain. More than 
100 proteins have been identified as ataxin-3 interacting partners, which elucidates the multiple 
biological functions of ataxin-3, however, knockout mouse models have revealed that it is not 
an essential protein [48, 50]. The major roles of ataxin-3 involve cellular protein quality control, 
regulation of ubiquitination status of several proteins and cellular response to heat stress [51, 
52]. Moreover, ataxin-3 is involved in aggresome production, cytoskeletal organization, 
endoplasmic reticulum-associated degradation and transcriptional regulation, as well [48]. 
Ataxin-3 interacting partners include E3 ligases (e.g., CHIP and parkin), which are associated 
with neurodegenerative disorders [53, 54]. The pathomechanism, how the polyQ tract leads to 
the development of the disease, is still unclear. Animal models of polyglutamine ataxin-3 
showed alterations in DUB function (enhancement or reduction), increased capability of nuclear 
aggregation, increased susceptibility to proteolysis resulting in the production of polyQ-
containing fragments, in the reduction of CHIP and parkin levels in the brain, and in altered 
DNA binding and consequent changes in the regulation of RNA transcription [48]. These 
functional abnormalities are a mixture of gain-of-function and loss-of-function alterations (Fig. 
3). 
Previously described studies using lentivirus expressing shRNAs targeting the ATXN3 gene in 
rat and mouse models were promising, because allele-specific shRNA prevented inclusion body 
formation, neuronal loss, and improved motor deficits, while both allele-specific and non-
allele-specific shRNAs reduced neuropathological abnormalities [55-57]. In addition, two other 
RNAi studies were performed using AAV vectors expressing miRNAs targeting the ATXN3 
gene in transgenic mouse and rat models. Allele-specific short-term suppression of ATXN3 
reduced the nuclear accumulation of cerebellar ataxin-3 protein, however, the well-tolerated 
lifelong gene suppression did not prevent motor abnormalities [58, 59]. Moreover, an ASO 
targeting ATXN3 in transgenic mice reduced polyQ containing ataxin-3 protein levels and 
prevented its nuclear accumulation, and furthermore, motor symptoms were also rescued [60]. 
Besides these genetic therapies, administering lactulose and melibiose in cell models resulted 
in a reduction in the aggregation of polyQ ataxin-3, which suggests the therapeutic potential of 
these trehalose analogs [61]. 
Ataxin-3 is not an essential protein, consequently reducing the levels of mutant ataxin-3 protein 
seems to be a favourable therapeutic option. The previously demonstrated animal model studies 
reinforce this hypothesis, so it would be a possible treatment option for SCA3 patients. 
SCA6 
Among the polyQ SCAs, SCA6 has the latest onset, usually beginning in the mid-40s. This is 
a pure cerebellar syndrome with a slow progression rate. Ataxia, dysarthria and nystagmus are 
the main signs, whereas tremor and mild somatosensory deficits may infrequently be observed. 
Pathological studies reveal that the principal abnormalities are located in the Purkinje cell layer 
of the cerebellum and in the primary motor cortex, while pontine, bulbar and deep cerebellar 
nuclei are mildly involved, and the diencephalon and the basal forebrain are relatively spared 
[15]. Due to the slight brainstem damage, in contrast to SCA1-3, SCA6 does not substantially 
reduce lifespan [62]. 
SCA6 is caused by CAG repeat expansion in the CACNA1A gene, located on chromosome 19. 
Normal alleles contain 18 or fewer CAG repeats, while full penetrance alleles comprise 20-33 
CAG repeats, and alleles with 19 CAG repeats have questionable significance [63, 64]. Besides 
SCA6, CACNA1A gene mutations can lead to the development of other autosomal dominant 
neurological disorders, including episodic ataxia type 2, familial hemiplegic migraine type 1 
and early infantile epileptic encephalopathy type 42.  
The CACNA1A gene encodes a bicistronic mRNA, which can be translated into two distinct 
proteins, the transmembrane pore-forming alpha-1A subunit of the voltage-dependent calcium 
channel (Cav2.1 or VGCC) and the transcription factor α1ACT, which is under the control of 
an internal ribosomal entry site (IRES) (Fig. 4) [65, 66]. The Cav2.1 calcium channel is highly 
expressed in the Purkinje cells and the granule cells of the cerebellar cortex. The fundamental 
role of these P/Q-type calcium channels is synaptic transmission. α1ACT is translocated to the 
nucleus and enhances the expression of several genes playing roles in the development and 
differentiation of Purkinje cells [66]. Both of CACNA1A-encoded proteins contain the polyQ 
tract in their C-terminus. This C-terminal polyglutamine expansion does not cause abnormality 
in the function of the calcium channel, however the polyQ-containing cytoplasmic carboxy 
terminus is cleaved, and the generated peptide is transported to the nucleus, producing toxic 
effects. In addition, the polyQ tract in α1ACT alters its gene-binding ability, causing a 
deterioration of its transcriptional function and contributing to the development of disease (Fig. 
4). 
Miyazaki et al. reported an RNAi study using an AAV vector expressing miRNA-targeted IRES 
of the CACNA1A gene in a mouse model with early-onset SCA6. This research demonstrated 
that the reduced translation of α1ACT blocks the interaction between IRES and eukaryotic 
initiation factors (eIFs), preventing motor abnormalities and Purkinje cell pathology [67]. 
The polyQ containing peptides (α1ACT and the cleaved cytoplasmic carboxy terminus) play 
major roles in the pathogenesis. Reducing the levels of these proteins is an attractive therapeutic 
option. This can be achieved in many ways, including the modification of transcriptional, 
translational and posttranslational regulation or the specific binding and degradation of 
proteins.  
SCA7 
SCA7 basically begins in the third decade of life, however marked anticipation is known, which 
can be so pronounced that a child may be symptomatic years before a parent or grandparent 
developed any symptoms of the disease [68]. The most characteristic clinical alterations are 
retinal degeneration and visual impairment, which eventually lead to blindness. 
Ophthalmoparesis, pyramidal signs, dysphagia, bulbar symptoms and urinary dysfunction are 
also present, in addition to the progressive cerebellar ataxia. Pathological studies presented mild 
degeneration of the supratentorial structures and the deep cerebellar nuclei, whereas brainstem 
nuclei and Purkinje cells were severely affected [15]. The progressive retinal degeneration is 
explained by cone-rod dystrophy, which is a unique pathological finding in SCA7 among SCAs 
[69]. 
The genetic background of SCA7 is the CAG repeat expansion in the ATXN7 gene located on 
chromosome 3. Normal alleles maximally contain 19 CAG repeats, while the most prevalent 
repeat size is 10 [70]. Full-penetrance pathogenic alleles consist of greater than 36 CAG repeats 
[71]. Alleles between 28 and 36 repeats are called intermediate alleles with mutable normal (28 
to 33) and reduced-penetrance features (34 to 36), whereas there is no available data regarding 
the significance of 20 to 27 repeats [72].  
The protein ataxin-7, encoded by the ATXN7 gene, is a 95 kDa molecule containing 892 amino 
acids (in the case of 10 CAG repeats) (Fig. 5). Ataxin-7 is a component of nuclearly localized 
multi-subunit complexes (TFTC and STAGA) having histone acetyltransferase and 
deubiquitinase activity [73]. The intracellular distribution of ataxin-7 varies between the 
nucleus and the cytoplasm, in the latter connecting with the microtubules and stabilizing them 
[74]. Lan et al. reported that in vitro polyQ tract containing ataxin-7 does not change DUB 
activity of the protein complex. However, in vivo mouse models revealed that polyQ ataxin-7 
prefers the formation of insoluble aggregates that separate the DUB module of the protein 
complex, resulting in increased levels of ubiquitinated histone 2 B (H2B) [75]. These alterations 
in enzymatic activity can cause abnormalities in gene expression, leading to the development 
of disease (Fig. 5). 
Recent RNAi studies used AAV vector-delivered non-allele specific miRNAs targeting ATXN7 
in a transgenic mouse model. The therapeutic construct was injected into the retina or the deep 
cerebellar nuclei of the mice. Both treatments were beneficial, in the first case, normal retinal 
function was preserved and there was no adverse effect, whereas cerebellar delivery resulted in 
improvement of motor deficits and amelioration of Purkinje cell abnormalities [76, 77]. 
Further examinations are needed for extensive understanding of the disease pathomechanism 
and to discover which molecules can regulate the function of ataxin-7. Besides these potential 
targets, promising RNAi animal model studies may provide another hopeful treatment option 
to ameliorate the symptoms of SCA7 patients. 
SCA17 
SCA17 is also called Huntington disease-like 4 (HDL4) according to the clinical phenotype 
resembling Huntington’s disease (HD). The major extracerebellar symptoms are chorea, 
dystonia, parkinsonism, seizures, pyramidal signs, dysphagia, deep sensory deficits, autonomic 
failure and cognitive impairment. The mean age of onset is the mid-30s. Pathological 
examinations revealed neuronal loss in the substantia nigra, striatum, ventral thalamic nuclei, 
inferior olive, Purkinje cell layer and in the cingulate and parahippocampal gyri [15].  
DRPLA 
Dentatorubral-pallidoluysian atrophy usually begins at 28-30 years, and may be characterized 
by prominent anticipation as well [78, 79]. The typical non-cerebellar symptoms are chorea, 
myoclonus, dystonia, cognitive decline and seizures. The juvenile-onset (before the age of 20) 
is characterized by progressive myoclonus epilepsy and mental retardation, whereas the later-
onset form is associated with ataxia, chorea and dementia [80]. The name of the disease 
indicates that the dentatorubral and pallidoluysian systems are affected, and furthermore, 
diffuse white and grey matter loss was also observed [15]. 
2.2. Repeat expansion in the non-coding region 
This is a less frequent group of SCAs, containing slowly progressive disorders with only mild 
or no anticipation. In contrast to the polyQ SCAs, there is a little scientific information about 
the pathomechanism or potential therapeutic targets of these diseases, and accordingly, this part 
mainly focuses on the main clinical characteristics of these disorders. 
SCA8 
SCA8 is a slowly progressive ataxia without the phenomenon of anticipation. The disease most 
commonly starts in the fourth decade of life. Patients exhibit cerebellar symptoms including 
gait and limb ataxia, dysarthria and nystagmus, while the most frequent extracerebellar features 
are pyramidal signs, cognitive impairment, ophthalmoparesis and deep sensory abnormalities. 
Brain MRI scans revealed pronounced cerebellar atrophy without brainstem or cerebral 
involvement. Pathological evaluation demonstrated the loss of Purkinje cells and cerebellar 
granular cells with degeneration of inferior olive and milder involvement of neurons of the 
substantia nigra [15, 81]. 
SCA10 
SCA10 is a rare disorder caused by pentanucleotide (ATTCT) repeat expansion and exclusively 
found in Latin American populations [82]. The first symptoms of SCA10 typically appear at 
the age of 32-34 years, however anticipation was observed in a number of families [83, 84]. 
The main feature, along with cerebellar ataxia, is rare epilepsy, which is a special sign amongst 
SCAs. Brain MRI examination showed pancerebellar atrophy without extracerebellar 
involvement, while pathological data are currently unavailable [15]. 
SCA12 
SCA12 is characterized by the onset of action tremor of the hand mainly at the age of 37-40 
years. In the next years, SCA12 patients develop slowly progressive ataxia and cerebellar 
oculomotor abnormalities, while a subset of patients has parkinsonism, pyramidal signs and 
dementia. Most of the SCA12 patients were published from the Indian population and an 
American family of German origin [85-87]. Brain MRI demonstrates atrophy of both the 
cerebral cortex and the cerebellum, mainly in the vermis [88]. Postmortem neuropathological 
examination from one SCA12 patient revealed enlarged ventricles, cerebral cortical atrophy 
with milder cerebellar and pontine atrophy [89]. 
SCA31 
SCA31 is the third most common SCA in the Japanese population with a general onset in the 
sixth decade. This pentanucleotide repeat expansion disease is characterized by a purely 
cerebellar syndrome with slow deterioration rates and cerebellar atrophy observed in brain 
MRI. The few available neuropathological data demonstrated marked Purkinje cell loss [15, 
90]. 
SCA36 
SCA36 is caused by a hexanucleotide (GGCCTG) repeat expansion with mean age of onset at 
the 52-53 years. This subtype of SCA is a slowly progressive cerebellar syndrome with hearing 
loss and lower motoneuron signs, of which the latter two are relatively specific symptoms in 
this group. Brain MRI scans revealed mild cerebellar atrophy, while pathological examinations 
showed neuronal loss of the Purkinje cell layer and the dentate nucleus [91]. 
SCA37 
SCA37 has a relatively pure cerebellar entity with vertical eye movement abnormalities. To 
date, only a large Spanish family was identified as having SCA37, in whom the onset of the 
disease varied between 25-64 years. Brain MRI investigations revealed initial vermis atrophy 
progressing to generalized cerebellar atrophy without extracerebellar involvement. Postmortem 
pathological examinations from two SCA37 patients demonstrated extensive loss of Purkinje 
cells, neuronal loss and gliosis in the inferior olive [92].  
 
2.3. Non-repeat expansion SCAs 
This group of SCAs is caused by conventional mutations resulting in a slowly progressive 
clinical phenotype, not interfering with the lifespan of the patient. Anticipation was not 
observed in these neurodegenerative disorders. Most of these subtypes were described in the 
new generation sequencing era. Besides the considerably novel delineation of these disorders, 
their rarity also contributes to the fact that few studies have been carried out to discover the 
deep pathomechanism of these diseases which would be the fundamental basis of therapeutic 
investigations. Accordingly, the following part mainly focuses on clinical findings. 
SCA5 
In SCA5, the age of onset varies from childhood to adulthood, with an average onset at 19-24 
years. SCA5 is characterized by cerebellar symptoms with a little brainstem or spinocerebellar 
tract involvement. Patients with juvenile-onset developed pyramidal signs and bulbar 
dysfunction causing a severe phenotype [93]. Brain MRI studies revealed cerebellar cortical 
atrophy with a disproportionately massive reduction in the volume of the anterior vermis and 
the superior hemispheres [94]. Neuropathological examinations confirmed the imaging data 
with the observation of markedly reduced cerebellar weight and severe atrophy of the anterior 
vermis and adjacent cerebellar hemispheres [94, 95]. 
SCA11 
SCA11 is a slowly progressive cerebellar ataxia, which generally begins in the fifth decade of 
life. Besides cerebellar ataxia, jerky pursuit, horizontal and vertical nystagmus are the most 
common findings, while pyramidal signs, peripheral neuropathy and dystonia only occasionally 
occur [96]. Brain MRI studies revealed cerebellar atrophy with vermal predominance [97]. 
Pathological investigations demonstrated Purkinje and granular cell loss in the cerebellar cortex 
and neuronal loss in the dentate nucleus [15].  
SCA13 
SCA13 is a rare type of SCA with two different phenotypes. Patients from a French family can 
be characterized by childhood-onset cerebellar ataxia and mental retardation with a slow 
progression, while patients from the Filipino family developed adult-onset (22-60 years) 
cerebellar ataxia and dysarthria [98, 99]. Mental retardation is an uncommon feature in 
autosomal dominant cerebellar ataxias, in contrast with the recessively-inherited forms. In 
addition, myoclonus and spasticity seem to be relatively prevalent findings in SCA13 [100-
102]. The age of onset and clinical phenotype of the disease depend on the type of mutation. 
Brain MRI revealed cerebellar atrophy with variable severity, whereas pathological 
examinations were not available. 
SCA14 
SCA14 typically begins around the age of 30 years with slowly worsening gait ataxia and later 
accompanied by dysarthria, limb ataxia, cerebellar oculomotor abnormalities and 
extrapyramidal symptoms including myoclonus and dystonia. In a few cases of SCA14, facial 
myokymia, deafness, cognitive deficit, depression and deep sensory loss were also observed. 
Brain MRI examinations evaluated cerebellar atrophy predominantly in the vermis. Detailed 
neuropathological studies are not available [15, 103]. 
SCA15/16 
SCA15/16 is a very slowly progressive type of SCAs with relatively pure cerebellar symptoms. 
The most frequent additional neurological sign in SCA15/16 is postural or kinetic tremor of the 
head or upper limb, with occasional occurrence of hyperreflexia and posterior column signs. 
The disease onset ranges from childhood to adulthood with an average of 31 years. Brain MRI 
scans demonstrated vermal atrophy with relatively spared cerebellar hemispheres and 
extracerebellar structures. No neuropathological examination has been published on these 
patients [15, 104].  
SCA19/22 
SCA19/22 is a slowly progressive SCA characterized by cerebellar ataxia, dysarthria, cognitive 
impairment and frontal lobe dysfunction. In a subset of patients, myoclonus, head tremor, 
pyramidal signs, parkinsonism, neuropathy and rarely epilepsy can develop [105]. Brain MRI 
investigations revealed vermal atrophy, while postmortem neuropathological examination 
evaluated the atrophy of the frontal lobe and the cerebellar cortex, and moreover, moderate 
dopaminergic neuronal loss of substantia nigra and severe loss of Purkinje cells predominantly 
in lobules 1-8 were described as well [106]. 
SCA21 
SCA21 is an early-onset (1-30 years, mean: 14-18 years) slowly worsening cerebellar ataxia, 
frequently associated with severe cognitive deficit, delayed psychomotor development and 
parkinsonism. Most of the SCA21 patients were described in the French population, only one 
Chinese person and one Japanese family with six affected individuals were reported. Brain MRI 
scans demonstrated cerebellar atrophy mainly affecting the vermis and to a lesser extent, the 
hemispheres [107-109]. Neuropathological investigations of one patient revealed severe loss of 
Purkinje cells and mild involvement of inferior olive neurons [108]. 
SCA23 
SCA23 was first described in a large Dutch family, whereas only some patients were reported 
from other ethnicities (1 British, 1 French and 1 Moroccan) [110-112]. This is a late-onset (49-
56 years) slowly progressive, mainly isolated cerebellar ataxia with some additional features 
including slowing of saccades, ocular dysmetria, dysarthria, pyramidal signs and deep sensory 
deficits. Brain MRI revealed cerebellar atrophy, and the neuropathological examination 
demonstrated neuronal loss in the Purkinje cell layer, dentate nuclei and inferior olive [113]. 
SCA26 
SCA26 was first reported in a six-generation family of Norwegian ancestry manifested by 
slowly worsening pure cerebellar ataxia without extracerebellar symptoms [114]. 
Neuropathological investigation of two patients from this population was performed and 
revealed significant Purkinje cell loss, whereas other brain regions were relatively spared [115]. 
SCA27 
SCA27 is an extremely slowly progressive neurodegenerative disease starting with postural 
hand tremor between the ages of 6-20 years, while ataxia developed only some decades later. 
In addition, head titubation, dyskinesia, reduced vibratory sense, cognitive impairment and 
behavioural abnormalities were also observed in some patients suffering from SCA27. Brain 
MRI examinations delineated moderate cerebellar atrophy only in the later stages of the 
disorder, whereas neuropathological studies are not available [116]. 
SCA28 
SCA28 is a very slowly deteriorating type of SCAs with variable age of onset (3-70 years, 
mean: 30.15 years). SCA28 is characterized by gait and limb ataxia, dysarthria, nystagmus, 
ptosis, ophthalmoparesis and pyramidal signs [117]. Brain MRI revealed mild to moderate 
cerebellar atrophy predominantly in the vermis. whereas postmortem pathological data are not 
available [118].  
SCA29 
SCA29 is an infantile-onset non-progressive disease characterized by hypotonia, motor delay, 
cognitive impairment and cerebellar abnormalities. Brain MRI scans demonstrated cerebellar 
atrophy mainly in the vermis and in the superior part of cerebellar hemispheres [119, 120]. 
SCA34 
SCA34 is a rare form of SCA, only two large French-Canadian and two Japanese SCA34 
families have been reported in the literature so far. In the French-Canadian pedigree, the 
affected patients presented ataxia and erythrokeratodermia variabilis, in the following order: 
the dermatological abnormalities were the initial signs, developing in infancy, while ataxia and 
mild peripheral axonal neuropathy appeared only in the fourth or fifth decade of life. In the 
Japanese population, erythrokeratodermia was absent, while pyramidal signs and hot cross bun 
sign on the brain MRI were present [121, 122]. 
SCA35 
SCA35 is a slowly progressive spinocerebellar ataxia reported in several Chinese families and 
in some Caucasian patients. Age of onset ranges from 12 to 56 years. The disease is 
characterized by gait and limb ataxia, hand tremor, dysarthria, mild mental retardation, 
myoclonus, spasticity and vermis atrophy on the MRI scans [123, 124]. Postmortem 
pathological data are not available. 
SCA38 
SCA38 was identified in a few Italian families and can be characterized by gait ataxia, 
dysarthria, horizontal and vertical nystagmus, pes cavus, hyposmia and in a third of the patients, 
hearing loss and anxiety. The most prevalent initial symptom was imbalanced gait occurring 
with a variable age of onset (26-50 years). In later stages of the disease, dysphagia, 
ophthalmoparesis, sensory loss and sometimes, pyramidal symptoms also developed with slow 
progression rates. Brain MRI revealed mild cerebellar atrophy with predominance in the vermis 
[125]. 
SCA42 
SCA42 is a slowly deteriorating disorder, recently identified in French, Japanese and Chinese 
families. The most prevalent symptom at onset was gait instability, whereas a relatively pure 
cerebellar phenotype with additional pyramidal signs, orbicular myokymia and rarely, with 
mild sensory deficits, dysphagia and urinary dysfunction may also be observed in the course of 
the disease. Brain MRI demonstrated cerebellar atrophy with vermal predominance, whereas 
postmortem pathological studies have not been performed so far [126-128]. 
SCA40, 41, 43, 44-47 
In these subtypes of SCAs, a very limited number of case reports have been published yet. 
Because of the few available clinical data, the detailed phenotypical characterization is lacking. 
2.4. Other SCAs (SCA4, 18, 20, 25, 30, 32) 
These infrequent SCAs were described in some families, whereas only the genetic loci were 
identified by linkage analysis studies. Nevertheless, the accurate disease-causing genes were 
not determined making the recruitment of a larger number of patients to further clinical and 
molecular studies difficult. 
3. Conclusion 
The number of subtypes of spinocerebellar ataxias has significantly increased in the last decades 
along with the development of genetics. This genetic information has allowed the differential 
diagnosis of SCAs, more difficult to perform based on clinical findings. Moreover, several 
novel disease-causing genes were identified, however, the pathological mechanisms are only 
partially discovered in the new forms of SCA. Nevertheless, the most common polyQ SCAs 
have been extensively researched in the past years, similarly to HD. The increasing scientific 
information and experience about polyQ SCAs and the availability of novel gene suppression 
therapies, including RNAi and ASO, has opened a new chapter in the treatment of CAG repeat 
expansion neurodegenerative disorders. The initiation of clinical trials with these new 
therapeutic approaches requires many patients, thereby international patient registries are 
essential. In addition, further clinical and preclinical studies are needed to profoundly recognize 
the rarer subtypes of SCAs with the possibility of therapeutic achievements in the future. 
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